GT201400059A - Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos - Google Patents

Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos

Info

Publication number
GT201400059A
GT201400059A GT201400059A GT201400059A GT201400059A GT 201400059 A GT201400059 A GT 201400059A GT 201400059 A GT201400059 A GT 201400059A GT 201400059 A GT201400059 A GT 201400059A GT 201400059 A GT201400059 A GT 201400059A
Authority
GT
Guatemala
Prior art keywords
preparation
procedures
tetraen
estra
carboxamide
Prior art date
Application number
GT201400059A
Other languages
English (en)
Inventor
Bothe Ulrich
Barak Naomi
Busemann Matthias
Fischer Oliver Martin
Rotgeri Andrea
Gashaw Isabella
Hartung Ingo
Marquardt Tobias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400059(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400059A publication Critical patent/GT201400059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

LA INVENCIÓN SE REFIERE A INHIBIDORES DE AKR1C3 Y A PROCEDIMIENTOS PARA SU PREPARACIÓN, SU USO PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE ENFERMEDADES, ASÍ COMO SU USO PARA LA PREPARACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE ENFERMEDADES, EN ESPECIAL DE TRASTORNOS HEMORRÁGICOS Y ENDOMETRIOSIS.
GT201400059A 2011-09-29 2014-03-28 Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos GT201400059A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011083725A DE102011083725A1 (de) 2011-09-29 2011-09-29 Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Publications (1)

Publication Number Publication Date
GT201400059A true GT201400059A (es) 2015-02-17

Family

ID=46963705

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400059A GT201400059A (es) 2011-09-29 2014-03-28 Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos

Country Status (42)

Country Link
US (1) US9487554B2 (es)
EP (1) EP2760878B1 (es)
JP (1) JP5791810B2 (es)
KR (1) KR20140069013A (es)
CN (1) CN103827133B (es)
AP (1) AP2014007598A0 (es)
AR (1) AR088180A1 (es)
AU (1) AU2012314627B2 (es)
BR (1) BR112014007223A2 (es)
CA (1) CA2850047C (es)
CL (1) CL2014000775A1 (es)
CO (1) CO6920294A2 (es)
CR (1) CR20140144A (es)
CU (1) CU20140037A7 (es)
CY (1) CY1117123T1 (es)
DE (1) DE102011083725A1 (es)
DK (1) DK2760878T3 (es)
DO (1) DOP2014000059A (es)
EA (1) EA025518B9 (es)
EC (1) ECSP14013275A (es)
ES (1) ES2560257T3 (es)
GT (1) GT201400059A (es)
HK (1) HK1197414A1 (es)
HR (1) HRP20160050T1 (es)
HU (1) HUE026645T2 (es)
IL (1) IL231755A (es)
JO (1) JO3122B1 (es)
MA (1) MA35455B1 (es)
MX (1) MX2014003823A (es)
MY (1) MY175804A (es)
PE (1) PE20141554A1 (es)
PL (1) PL2760878T3 (es)
PT (1) PT2760878E (es)
RS (1) RS54521B1 (es)
SG (1) SG11201400144SA (es)
SI (1) SI2760878T1 (es)
TN (1) TN2014000131A1 (es)
TW (1) TWI537284B (es)
UA (1) UA107550C2 (es)
UY (1) UY34356A (es)
WO (1) WO2013045407A1 (es)
ZA (1) ZA201401568B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512169B2 (en) 2012-07-10 2016-12-06 Bayer Pharma Aktiengesellschaft 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
BR112015018071A2 (pt) * 2013-02-21 2017-07-18 Bayer Pharma AG estra-1,3,5(10),16-tetraeno-3-carboxamidas
JP6407415B2 (ja) * 2014-09-11 2018-10-17 バイエル・ファルマ・アクティエンゲゼルシャフト ３−窒素または硫黄置換エストラ−１，３，５（１０），１６−テトラエンａｋｒ１ｃ３阻害剤
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) * 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
US20200085791A1 (en) 2016-12-19 2020-03-19 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
WO2018114672A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN108503695B (zh) * 2018-03-09 2021-06-08 南方医科大学南方医院 基于GnRH多肽衍生物的示踪剂及其制备方法和应用
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN113683648A (zh) * 2021-08-26 2021-11-23 上海皓鸿生物医药科技有限公司 一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632003A (en) 1985-07-15 1986-12-30 Kopp William L Musical instrument sound quality enhancement device
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
EP0633893B1 (en) * 1992-03-31 1999-11-24 Btg International Limited 17-substituted steroids useful in cancer treatment
BR9908592A (pt) 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
WO2005089256A2 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
RU2453554C2 (ru) * 2006-11-30 2012-06-20 Зольвай Фармасьютиклз Гмбх Замещенные производные эстратриена как ингибиторы 17бета hsd
WO2009120565A2 (en) 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
DK2563803T3 (en) 2010-04-27 2016-05-30 Pharma Mar Sa Anticancer-steroidal lactones, which is unsaturated at position 7 (8)

Also Published As

Publication number Publication date
AR088180A1 (es) 2014-05-14
BR112014007223A2 (pt) 2017-04-04
US20140249119A1 (en) 2014-09-04
MA35455B1 (fr) 2014-09-01
CN103827133A (zh) 2014-05-28
PL2760878T3 (pl) 2016-04-29
ES2560257T3 (es) 2016-02-18
CU20140037A7 (es) 2014-07-30
PE20141554A1 (es) 2014-10-24
MY175804A (en) 2020-07-09
JP2014527994A (ja) 2014-10-23
CA2850047C (en) 2016-03-29
NZ622081A (en) 2015-10-30
ZA201401568B (en) 2016-11-30
DOP2014000059A (es) 2014-06-15
JP5791810B2 (ja) 2015-10-07
DK2760878T3 (en) 2016-01-25
AU2012314627A1 (en) 2014-04-10
EA025518B1 (ru) 2016-12-30
AU2012314627B2 (en) 2016-08-18
UA107550C2 (uk) 2015-01-12
AP2014007598A0 (en) 2014-04-30
TWI537284B (zh) 2016-06-11
EA025518B9 (ru) 2017-10-31
JO3122B1 (ar) 2017-09-20
HRP20160050T1 (hr) 2016-02-12
WO2013045407A1 (de) 2013-04-04
KR20140069013A (ko) 2014-06-09
CA2850047A1 (en) 2013-04-04
RS54521B1 (en) 2016-06-30
CL2014000775A1 (es) 2014-08-18
EA201490653A1 (ru) 2014-09-30
MX2014003823A (es) 2014-06-04
ECSP14013275A (es) 2014-04-30
TN2014000131A1 (en) 2015-07-01
US9487554B2 (en) 2016-11-08
SI2760878T1 (sl) 2016-02-29
CR20140144A (es) 2014-05-16
IL231755A (en) 2016-06-30
HUE026645T2 (en) 2016-07-28
SG11201400144SA (en) 2014-05-29
CO6920294A2 (es) 2014-04-10
PT2760878E (pt) 2016-02-26
HK1197414A1 (zh) 2015-01-16
CY1117123T1 (el) 2017-04-05
CN103827133B (zh) 2015-11-25
EP2760878B1 (de) 2015-10-28
DE102011083725A1 (de) 2013-04-04
UY34356A (es) 2013-04-30
EP2760878A1 (de) 2014-08-06
TW201317253A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CR20150007A (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20150326A (es) Inhibidores de autotaxina
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
NI201400032A (es) Piridopirazinas anticancerígenas via la
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
IN2014DN06501A (es)
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
UY31922A (es) Compuestos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
BR112016005361A8 (pt) inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos